Ischemia Modified Albumin In The Early Diagnosis Value Of Non St Elevation Acute Coronary Syndrome

Objective:To research the early diagnostic value of ischemia modified albumin for non-ST-segment elevation acute coronary syndromes.Methods:The study group consisted of 177 patients, who were admitted to our department within six hours of possible non-ST-segment elevation acute coronary syndromes. The patients had laboratory tests performed including troponin I and IMA concentration. IMA was determined by the albumin cobalt binding (ACB) test. Patients underwent standardized triage, diagnostic procedures and treatment, and then were divided into 3 groups:group 1 with NSTEMI, group 2 with UA and group 3 with NICP. The patients in group 1 were evaluated by GRACE risk score.With the results of IMA, ROC curve analysis was used to determine the optimal cutoff of this assay for identifying patients with NSTEACS from those with NICP. Results of IMA, ECG and cTnI were correlated with final diagnosis and their diagnostic sensitivity, specificity, were evaluated for NSTEACS.Results:he IMA concentration in the serum did not differ significantly between NSTEMI and UA, whereas the two groups both differed significantly from NICP. Sensitivity and specificity at a cutoff point 67.49 U/mL were 91.1% and 86.2%. The correlation between the IMA concentration and GRACE risk score was positive.Conclusion:IMA is an early sensitive maker for ACS and is an useful predictor of prognosis.